

# MI3 Market Alert: Developing novel therapeutics for the treatment of chronic cough

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [BELLUS Health Inc.](#) (Nasdaq: BLU | TSX: BLU) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on BELLUS Health Inc.

- BELLUS Health is developing BLU-5937, a P2X3 inhibitor, to help people with chronic cough and other afferent hypersensitization-related disorders.
- In September 2019, BELLUS Health completed an offering of its common shares resulting in gross proceeds to the Company of US\$79.4 million and BELLUS Health's common shares began trading on the Nasdaq
- Cash, cash equivalents and short-term investments totalling **C\$132.2 million** (US\$99.9 million)
- Only 54M shares outstanding
- RSI at 41... Well position
- Support: S2; \$7.45      S1; \$8.06      Resistance:  
R1; \$ 8.14 – R2; \$8.50 – R3; \$8.99



## About BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

Chronic cough is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having refractory chronic cough lasting for more than a year. There is no specific therapy approved for refractory chronic cough and treatment options are limited.

Chronic pruritus, commonly known as chronic itch, is an

irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many conditions, including AD. It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.

## **PLEASE DO YOUR DUE DILIGENCE**

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

# **MI3 Market Alert: Rapid Pathogen detection system**

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [LexaGene Holdings Inc.](#) (TSXV: LXG | OTCQB: LXXGF) for

exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on LexaGene Holdings Inc.

- LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
- LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital.
- This placement marks a very significant milestone for the Company and for the diagnostics industry.
- LXG close a 6.64 Million with Industrial Alliance securities
- Support: S2; \$ 0.45 – S1; \$ 0.47      Resistance:    R1; \$ 0.50 –    R2; \$0.545



## **About LexaGene Holdings Inc.**

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press 'go'. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

## **PLEASE DO YOUR DUE DILIGENCE**

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

# MI3 Market Alert: Building the largest hydroponic facility for the cannabis sector

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [FSD Pharma Inc.](#) (CSE: HUGE | OTCQB: FSDDD) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on FSD Pharma Inc.

- FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.
- FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019.
- Only 7M Outstanding, consolidating after rollback
- RSI at 33 definitely near OVERSOLD territory
- recent rebound from \$4.40 to \$9.20
- HUGE traded over 2.3 Million shares since rollback on Oct 16
- Support: S2; \$ 6.35      S1; \$ 7.50      Resistance:      R1;  
\$7.70      R2; \$8.15



## About FSD Pharma

FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet.

FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

## PLEASE DO YOUR DUE DILIGENCE

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

# MI3 Market Alert: Advancing the next Palladium mine

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [Platinum Group Metals Ltd.](#) (TSX: PTM | NYSE American: PLG) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on Platinum Group Metals Ltd.

- Platinum Group Metals Ltd. is the operator of the Waterberg Project, a bulk underground palladium and platinum deposit located in South Africa (large scale palladium dominant mine).
- Proven and probable reserves of 19.5M ounces of 4E



(Palladium, Platinum, Gold and Rhodium)

- Total all in cost 767US\$
- The Waterberg Project is supported by a group of strategic investors: IMPLATS (15% interest in the Waterberg project), JOGMEC (12.95% interest in the Waterberg project) and HOSKEN CONSOLIDATED INVESTMENTS (owns 30.2% of Platinum Group Metals)
- PTM stock traded over 1.6 Million shares between \$1.36 & \$2.71
- Support: S2; \$1,60      S1; \$1.85      Resistance:      R1; \$ 2.12      R2; \$2.50



## About Platinum Group Metals Ltd.

Platinum Group Metals Ltd. is the operator of the Waterberg Project, a bulk underground palladium and platinum deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, Mnombo,

JOGMEC and Hanwa. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium and gold. The Company recently founded Lion Battery Technologies in partnership with Anglo American Platinum to support the use of palladium and platinum in lithium battery applications.

#### **PLEASE DO YOUR DUE DILIGENCE**

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

**MI3 Market Alert: Next generation pharmaceutical products for unmet medical**

# needs

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [IntelGenx Technologies Corp.](#) (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Technologies Corp.

- IntelGenx's superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.
- IntelGenx is currently conducting scale-up activities for cannabis-infused oral film product for an anticipated commercial launch. With the recent Cannabis Act amendments authorizing the sale of new classes of cannabis products, including oral films, we are well-positioned participate in the expanded cannabis market just as new product formats come online.
- Rebounding since 70 cents ... next target \$0.93 ...Echelon Wealth Partners rate IGX at \$1.60
- Support: S2; \$0.70      S1; \$0.78      Resistance:      R1; \$0.89      R2; \$0.93



## About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

## PLEASE DO YOUR DUE DILIGENCE

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

# MI3 Market Alert: Top Gold Explorer in Nevada

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on [Corvus Gold Inc.](#) (TSX: KOR | OTCQX: CORVF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on Corvus Gold Inc.

- Corvus Gold Inc. is a North American gold exploration and development company, focused on its near-term gold-silver mining project at the North Bullfrog and Mother Lode Districts in Nevada.
- Near-term potential for mining complex to produce

2.6Mozs over 9 yrs with ~350Koz/yr for the first 4 years.

- On October 10<sup>th</sup> Corvus closes C\$23Million bought deal financing.
- KOR traded over 9.0 Million shares between \$1.90 & \$2.69
- Support: S2; \$ 1.72 S1; \$1.85 Resistance: R1; \$1.95 R2; \$2.05



## About Corvus Gold Inc.

Corvus Gold Inc. is a North American gold exploration and development company, focused on its near-term gold-silver mining project at the North Bullfrog and Mother Lode Districts in Nevada. Corvus is committed to building shareholder value

through new discoveries and the expansion of its projects to maximize share price leverage in an advancing gold and silver market.

## **PLEASE DO YOUR DUE DILIGENCE**

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*